Public private partnership- Marguerite Massinga Loembe, MSc, PhD

International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2018

Best practice talk; The Netherlands | Marc van der Valk, MD, PhD

International Viral Hepatitis Elimination Meeting (IVHEM) 2018

RNA Interference Screen Identified Farnesoid X Receptor (FXR) as a Host Dependency Factor for HBV Establishment in Primary Human Hepatocytes- Dr. S. Ghosh

HEP DART 2017

Evidence Supporting Liver Targeting of Tenofovir Exalidex (TXL)- Dr. R. Foster

HEP DART 2017

Two Doses of HEPLISAV-B™, a Hepatitis B Vaccine with a TLR9 Adjuvant, Compared with Three Doses of Alum-Adjuvanted ENGERIX-B® in Adults Aged 18 -70 Years- Dr. R. Hyer

HEP DART 2017

An Integrated Multidisciplinary Approach for Prediction of Fibrosis Progression and HCC Development in Chronic Hepatitis C Infected Patients Utilizing Genomics, Elastography, Imaging and Circulating Tumor Cells (not yet available)- Dr. E. Thomas

HEP DART 2017

Regulatory landscape for NASH- Veronica Miller

HEP DART 2017

Validation of a novel Transient Elastography for the measurement of liver fibrosis- Dr. J. Dong

HEP DART 2017

Establishment of functional control and normalization of liver function in HBeAg negative chronic HBV infection following combined therapy with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon α-2a.- Dr. A. Vaillant

HEP DART 2017

Strategy for the Elimination of Hepatitis B and C (Academy of Medicine Report)- Andrew Aronsohn, MD

HEP DART 2017

Elimination of HCV: The DC Story- Henry Masur, MD

HEP DART 2017

Eliminating Hepatitis C by 2030 - Enhancing prevention care and treatment among people who inject drugs- Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhD

HEP DART 2017

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition- Anna S. Lok, MD, DSc

HEP DART 2017

Global Strategies to Eliminate Hepatitis B (ICE-HBV)- Peter Revill

HEP DART 2017

Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drugs (PWID) in the United States (US): a mathematical model using data from the C-EDGE CO-STAR Study- Dr. M. Robertson

HEP DART 2017

The French and European Approach Towards Hepatitis Elimination- Tarik Asselah, MD, PhD

HEP DART 2017

Novel Nucleosides, CMCP and CFCP, Potently Block the Infectivity and Replication of Wild-type and Drug-resistant HBVs in Culture and in Human-liver-chimeric Mice and Show Potential QW or Q2W (not available)- Dr. H. Mitsuya

HEP DART 2017

Access to HIV, HBV, and HCV Antiviral Agents Globally- John Martin, PhD

HEP DART 2017

DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination- Jason Grebely

HEP DART 2017

Liver Disease in Chinese-perspective from a Hepatologist- George Lau, MBBS, MRCP, FHKCP, FHKAM, MD, FRCP

HEP DART 2017

A Tale of Two Viruses: HBV and HCV Co-infection (not available)- Jake Liang

HEP DART 2017

The Global Burden of Non-alcoholic Steatohepatitis (not available)- Zobair Younossi

HEP DART 2017

Short Duration DAA HCV Therapy: How Short Can We Go?- Shyam Kottilil, MD, PhD

HEP DART 2017

Elucidating the structural and dynamic mechanism of resistance for clinically relevant variants against HCV NS3/4A protease inhibitors (not available)- Dr. A. Matthew

HEP DART 2017